en · de · es · pt
melanotan-2-notes.peptides1004.com › Data › Background And Chemical Profile — Practical Notes

Background And Chemical Profile — Practical Notes

By Editorial Desk · published 2026-02-19 · last reviewed 2026-03-07 · Data

Melanotan II raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-03-07 and is reviewed periodically as new material appears.

Background and Chemical Profile

The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Melanotan-2 Identity And Regulatory Status

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Melanotan-2 at a glance

PropertyValueNotes
Molecular classSynthetic cyclic heptapeptideAnalog of alpha-MSH with an internal lactam bridge
Molecular weightApproximately 1024 daltonsFree base value; salt forms differ
AppearanceWhite to off-white powderUsually supplied as a lyophilized solid
SolubilityFreely soluble in waterPoorly soluble in nonpolar solvents
Typical storage−20 °C, dry, protected from lightRepeated freeze-thaw cycles degrade peptides

Peptide Identity and Structural Background

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

Related pages on this site

Chemical Background and Receptor Activity

Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.

Melanotan II Background and Mechanism

Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.

Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.

Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.

Reference notes

Ayahuasca is a South American psychoactive decoction prepared from Banisteriopsis caapi vine and a dimethyltryptamine (DMT)-containing plant, used by Indigenous cultures in the Amazon and Orinoco basins as part of traditional medicine and shamanism. The word ayahuasca, originating from Quechuan languages spoken in the Andes, refers both to the B. caapi vine and the psychoactive brew made from it, with its name meaning 'spirit rope' or 'liana of the soul'. Although often portrayed as ancient, ayahuasca likely spread across the western Amazon only within the past few centuries; the first clear written accounts appear in the 17th century. The specific ritual use of ayahuasca was widespread among Indigenous groups by the 19th century. Ayahuasca is traditionally prepared by macerating and boiling B. caapi with other plants like Psychotria viridis during a ritualistic, multi-day process. Ayahuasca has been used in diverse South American cultures for spiritual, social, and medicinal purposes, often guided by shamans in ceremonial contexts involving specific dietary and ritual practices, with the Shipibo-Konibo people playing a significant historical and cultural role in its use. Originally confined to regions of Peru, Brazil, Colombia, and Ecuador, ayahuasca became widespread in Brazil, expanding widely by the mid-20th century through syncretic religions in Brazil.

Peppermint was first identified in Hertfordshire, England, by a Dr. Eales, a discovery which John Ray published 1696 in the second edition of his book Synopsis Methodica Stirpium Britannicarum. He initially gave it the name Mentha spicis brevioribus et habitioribus, foliis Mentha fusca, sapore fervido piperis and later in his 1704 volume Historia Plantarum he called it Mentha palustris or Peper–Mint. The plant was then added to the London Pharmacopoeia under the name Mentha piperitis sapore in 1721. It was given the name Mentha piperita in 1753 by Carl Linnaeus in his Species Plantarum Volume 2. Linnaeus treated peppermint as a species, but it is now agreed to be a hybrid between Mentha aquatica and Mentha spicata, with M. spicata itself also being considered by some authors to be a hybrid between Mentha longifolia and Mentha suaveolens. Peppermint is a herbaceous, rhizomatous, perennial plant that grows to be 30–90 cm (12–35 in) tall, with smooth stems, square in cross section. The rhizomes are wide-spreading and fleshy, and bear fibrous roots. The leaves can be 4–9 cm (1.6–3.5 in) long and 1.5–4 cm (0.59–1.57 in) broad. They are dark green with reddish veins, with an acute apex and coarsely toothed margins. The leaves and stems are usually slightly fuzzy. The flowers are purple, 6–8 mm (0.24–0.31 in) long, with a four-lobed corolla about 5 mm (0.20 in) diameter; they are produced in whorls (verticillasters) around the stem, forming thick, blunt spikes. Flowering season lasts from mid- to late summer.

Shānghán Zábìng Lùn (傷寒雜病論), or The Treatise on Cold Damage and Miscellaneous Diseases, is the first Chinese monograph on diseases by Zhang Zhongjing. The original work is lost, but most of its contents are preserved in two extant works called Shānghán Lùn (傷寒論; "The Treatise on Cold Damage") and Jīnguì Yàolüè (金匱要略; "Essential Prescriptions from the Golden Chamber"). The first work primarily addresses externally triggered conditions while the latter work describes internally generated conditions. Zhang's specialized chapter on xiāo kě is found in Shānghán Lùn and Jīnguì Yàolüè. Nine subsections and nine formulae (herbal remedies) on wasting-thirst were recorded. The text proposed a theory of "three wasting-thirsts": upper- (associated with the lungs), middle- (associated with the stomach), and lower- (associated with the kidneys), all three of which shared excessive urine and thirst as symptoms. This theory was later expanded through the works of Liu Wansu (1120–1200 AD) and Wang Kentang (1549–1613 AD). According to Liu, "lower wasting-thirst" attributed to "kidney-yin deficiency" was associated with sweet urine (glycosuria). This may indicate differentiation akin to modern-day differentiation of diabetes mellitus and diabetes insipidus.

=== Measurement === As almost all DHEA is derived from the adrenal glands, blood measurements of DHEA-S/DHEA are useful to detect excess adrenal activity as seen in adrenal cancer or hyperplasia, including certain forms of congenital adrenal hyperplasia. Women with polycystic ovary syndrome tend to have elevated levels of DHEA-S.

Sources: en.wikipedia.org

Reference notes

=== Biofilm formation === Pseudomonas syringae produces polysaccharides which allow it to adhere to the surface of plant cells. It also releases quorum sensing molecules, which allows it to sense the presence of other bacterial cells nearby. If these molecules pass a threshold level, the bacteria change their pattern of gene expression to form a biofilm and begin expression of virulence-related genes. The bacteria secrete highly viscous compounds such as polysaccharides and DNA to create a protective environment in which to grow.

== Taxonomy == The name Artocarpus is derived from the Greek words artos ("bread") and karpos ("fruit"). This name was coined by Johann Reinhold Forster and J. Georg Adam Forster, a father-and-son team of botanists aboard HMS Resolution on James Cook's second voyage; they used it in their book Characteres generum plantarum. It is maintained as a conserved name. Although fossils of Artocarpus have been reported from as early as the Late Cretaceous, these fossils generally that lack key diagnostic characters such as that could definitively place them in the genus. The last common ancestor of all living Artocarpus likely originated in the vicinity of Borneo, from which Artocarpus dispersed elsewhere in Asia and Oceania.

The New York Times wrote that Biden's "weak filters make him capable of blurting out pretty much anything". According to The New York Times, Biden often embellishes elements of his life or exaggerates, a trait also noted by The New Yorker in 2014. For instance, he has claimed to have been more active in the civil rights movement than he actually was, and has falsely recalled being an excellent student who earned three college degrees. The Times wrote, "Mr. Biden's folksiness can veer into folklore, with dates that don't quite add up and details that are exaggerated or wrong, the factual edges shaved off to make them more powerful for audiences."

== See also == Allegations of corruption and bribery related to the 2022 FIFA World Cup Azerbaijani laundromat, a complex money laundering scheme for money used to pay off European politicians. Cash for influence Caviar diplomacy, a lobbying strategy of Azerbaijan, consisting of costly invitations to foreign politicians. Censorship in the European Union Foreign relations of Qatar Influence peddling Qatari connection affair Russian Laundromat, possibly the world's largest money-laundering scheme. Sekunjalo Investments, largest donor to Fight Impunity.

==== Non-deterministic wallet ==== In a non-deterministic wallet, each key is randomly generated independently and is not derived from a common seed. Therefore, any backups of the wallet must store each and every private key used as an address, as well as a buffer of future keys that may have already been issued as addresses but have not yet received payments.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

How does it differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.

Is it the same as bremelanotide?

No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.

Is melanotan II approved for medical use?

No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.

Network